Zoetis price to book ratio ZTS
Market value divided by the book value of the company's net assets, since 2013.
- Today, Nov 3, 2026
- 10.9×
- 10-year median
- 18.1×
- Against its 10-year history
- 8th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 9.1× to 26.4×
- Peer median
- 4.9×
Zoetis' price to book ratio is 10.9× as of Nov 3, 2026.
That is below its ten-year median of 18.1×, lower than on 92% of days in the last ten years.
Over that time it ranged from 9.1× in Oct 2026 to 26.4× in Oct 2020.
The median for 10 healthcare stocks of a similar size is 4.9×.
Price to book ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 10.9× | 9.1× | 16.6× |
| 2025 | 10.3× | 9.7× | 16.3× |
| 2024 | 14.2× | 13.4× | 18.1× |
| 2023 | 17.8× | 14.7× | 19.5× |
| 2022 | 14.6× | 13.4× | 21.3× |
| 2021 | 24.7× | 18.4× | 24.7× |
| 2020 | 21.8× | 17.7× | 26.4× |
| 2019 | 23.7× | 19.2× | 25.4× |
| 2018 | 19.2× | 17.7× | 23.4× |
| 2017 | 17.6× | 16.7× | 19.3× |
| 2016 | 16.7× | 15.3× | 22.6× |
| 2015 | 19.4× | 15.7× | 20.5× |
| 2014 | 16.2× | 13.4× | 19.3× |
| 2013 | 19.4× | 18.2× | 23.9× |
Against its peers
Companies in Healthcare nearest Zoetis' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ZTSZoetis | 10.9× |
| ILMNIllumina | 12.6× |
| MTDMettler-Toledo International | n/m |
| RMDResMed | 4.9× |
| GEHCGE HealthCare Technologies | 3.3× |
| CNCCentene | 1.5× |
| BIIBBiogen | 2.0× |
| DXCMDexCom | 12.2× |
| RPRXRoyalty Pharma | 5.7× |
| LHLabcorp | 3.4× |
| ONCBeOne Medicines | 7.8× |
| Peer median | 4.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Zoetis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.